US OptionsDetailed Quotes
RXRX241206C7500
- 0.16
- -0.04-20.00%
15min DelayClose Dec 4 16:00 ET
0.29High0.05Low
0.25Open0.20Pre Close1.08K Volume1.30K Open Interest7.50Strike Price16.22KTurnover131.76%IV7.43%PremiumDec 6, 2024Expiry Date0.00Intrinsic Value100Multiplier2DDays to Expiry0.16Extrinsic Value100Contract SizeAmericanOptions Type0.3094Delta0.5337Gamma57.04Leverage Ratio-0.0722Theta0.0001Rho17.65Eff Leverage0.0018Vega
Recursion Pharmaceuticals Stock Discussion
“The evolution of precision and personalized treatment options for oncology patients provide promising alternatives,” says William McKean, MD, Clinical Investigator at START Mountain Region in Salt Lake City, Utah. “We are so pleased to be working with Recursion as a participating site in the DAHLIA trial, and look forward to advancing the science of cancer treatment.”
$Recursion Pharmaceuticals (RXRX.US)$
$NVIDIA (NVDA.US)$
Goldman Sachs also pointed out in a previous report that by 2025, investors are expected to shift from AI infrastructure to a broader "t...
No comment yet